Losartan: Clinical Trials

76 trials of Losartan, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

33 completed, 14 terminated, 10 unknown, 6 active not recruiting. 76 Phase 2, 10 Phase 1, 9 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 276Completed 33, Terminated 14, Unknown 10, Active not recruiting 6, Recruiting 6, Not yet recruiting 3, Withdrawn 3, Suspended 1
Phase 110Terminated 3, Not yet recruiting 2, Recruiting 2, Completed 1, Suspended 1, Unknown 1
Phase 39Completed 3, Terminated 3, Recruiting 1, Unknown 1, Withdrawn 1

Follow Losartan: new trials by email Literature Review of Losartan trials Research Report on Losartan

Trials (filtered) newest first · largest first

All 76 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer
losartan, Paclitaxel - Platinum Resistant Ovarian Cancer
Phase 2Not yet recruitingMassachusetts General Hospital272027-02-012026-09-22
The GranStone Trial
empagliflozin (Jardiance) 25 mg, Losartan 100 mg - Paraffinoma, Granuloma, Foreign-Body
Phase 2 / Phase 3RecruitingMartin Blomberg Jensen1002026-10-202026-11-10
Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy
BreakVax, Ipilimumab 2.5 mg, Pembrolizumab - Glioblastoma (GBM)
Phase 1 / Phase 2Not yet recruitingBreakBio Corp102026-09-012026-08-19
Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy
BreakVax, Ipilimumab 2.5 mg, Pembrolizumab - Triple-Negative Breast Cancer (TNBC)
Phase 1 / Phase 2Not yet recruitingBreakBio Corp102026-09-012026-08-19
Losartan to Improve Outcomes After Multi-ligament Knee Injury
losartan 25 mg, Placebo capsule - Multi-ligament Knee Injury
Phase 2RecruitingBrigham and Women's Hospital902025-10-012026-01-20
Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.
Losartan, Placebo - Cystic Fibrosis
Phase 2RecruitingUniversity of Kansas Medical Center422024-06-032025-05-02
Polypill for Prevention of Cardiomyopathy
Polypill, Combined prescription of the individual medications - Type 2 Diabetes, High Blood Pressure
Phase 1 / Phase 2RecruitingUniversity of Texas Southwestern Medical Center2002024-03-112026-08-04
Mitigation of Arthrofibrosis After Total Knee Arthroplasty Using Losartan
Losartan, Placebo - Losartan - Knee Arthroplasty, Total
Phase 1 / Phase 2RecruitingSteadman Philippon Research Institute1202024-03-062024-03-12
Prevention of Paclitaxel-induced Peripheral Neuropathy in Breast Cancer Patients
Losartan - Peripheral Neuropathy Due to Chemotherapy
Phase 2CompletedFuture University in Egypt842023-12-122025-04-24
Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients
Losartan 25 milligram capsule, Placebo - Radiation Induced Fibrosis
Phase 2Active not recruitingShaw Cancer Center432023-08-172026-06-18
Effect of Losartan on the Incidence and Severity of Chemotherapy-Induced Mucositis in Gastrointestinal Cancer Patients
Losartan 50mg Tab - Chemotherapy, Colorectal Cancer
Phase 2UnknownAin Shams University802023-07-172023-07-19
GEM+Nab-Paclitaxel Plus Losartan Followed by Stereotactic Radiotherapy for Locally Advanced Pancreatic Cancer
Losartan, Gemcitabine, Nab paclitaxel - Pancreatic Cancer
Phase 2WithdrawnIstituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS2023-06-142024-12-27
Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)
Angiotensin II Receptor Blockers (ARBs, losartan) and Calcium Channel Blockers (CCB, amlodipine), PCP - Cognitively Normal Older Adults, Hypertension
Phase 2Active not recruitingRong Zhang1802022-10-252026-07-21
FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer
FOLFIRNINOX, Losartan, 9-ING-41 - Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma Metastatic
Phase 2Active not recruitingColin D. Weekes, M.D., PhD702022-03-212026-09-11
The Effect of Enalapril, Losartan or Not Antihypertensive on the Oxidative Status in Renal Transplant Recipients
Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers - Oxidative Stress
Phase 2CompletedUnidad de Investigacion Medica en Enfermedades Renales392022-01-012022-02-09
Camrelizumab in Combination With PLD and Losartan in Patients With TNBC Who Have Received ≦ 1 Line of Chemotherapy
Camrelizumab, Liposomal Doxorubicin, Losartan - Breast Cancer
Phase 2UnknownUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology522021-10-012021-10-28
Losartan for Diffuse Myocardial Fibrosis in Sickle Cell Disease
Losartan - Sickle Cell Disease, Diffuse Myocardial Fibrosis
Phase 2CompletedChildren's Hospital Medical Center, Cincinnati142021-09-012026-06-12
NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer
Capecitabine, Fluorouracil, Irinotecan Hydrochloride - Pancreatic Adenocarcinoma, Stage 0 Pancreatic Cancer American Joint Committee on Cancer v8
Phase 2Active not recruitingOHSU Knight Cancer Institute422021-05-272026-01-14
Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis
Fisetin, Losartan, Placebo - Losartan - Osteoarthritis, Knee
Phase 1 / Phase 2UnknownSteadman Philippon Research Institute1002021-05-182024-04-16
Losartan and Spironolactone Treatment for ICU Patients With COVID-19 Suffering From ARDS
Losartan 50 mg and Spironolactone 25 mg pillules oral use - COVID-19, ARDS
Phase 2TerminatedAssistance Publique Hopitaux De Marseille782020-09-112024-06-24

Showing 20 of 76. Sign in to see all of them.

Conditions studied

Hypertension (17)  ·  COVID-19 (6)  ·  Coronavirus Infections (4)  ·  Fibrosis (4)  ·  Kidney Diseases (4)  ·  Anemia, Sickle Cell (3)  ·  Breast Neoplasms (3)  ·  Inflammation (3)  ·  Non-alcoholic Fatty Liver Disease (3)  ·  Pancreatic Neoplasms (3)  ·  Alzheimer Disease (2)  ·  Camurati-Engelmann Syndrome (2)  ·  Cardiomyopathy, Hypertrophic (2)  ·  Cystic Fibrosis (2)  ·  Dementia (2)

Sponsors

Massachusetts General Hospital (5)  ·  Children's Hospital Medical Center, Cincinnati (4)  ·  Steadman Philippon Research Institute (3)  ·  University of Minnesota (3)  ·  BreakBio Corp (2)  ·  Hanmi Pharmaceutical Company Limited (2)  ·  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2)  ·  University of Alabama at Birmingham (2)  ·  University of Texas Southwestern Medical Center (2)  ·  Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1)  ·  Ain Shams University (1)  ·  Alicia Gerke (1)  ·  Assistance Publique Hopitaux De Marseille (1)  ·  Bassett Healthcare (1)  ·  Brigham and Women's Hospital (1)

Countries

United States (48)  ·  Canada (6)  ·  Italy (4)  ·  Taiwan (4)  ·  Brazil (3)  ·  Mexico (3)  ·  South Korea (3)  ·  Denmark (2)  ·  Egypt (2)  ·  Germany (2)  ·  Netherlands (2)  ·  Poland (2)  ·  Argentina (1)  ·  Chile (1)  ·  China (1)

Top investigators

Christopher Tignanelli, MD (2)  ·  Johnny Huard, PhD (2)  ·  Michael Puskarich, MD, MS (2)  ·  Rong Zhang, PhD (2)  ·  Adrian Camacho Ortiz, MD (1)  ·  Alicia K Gerke, MD (1)  ·  Ambarish Pandey, MD, MSCS (1)  ·  Antonino Romeo, MD (1)  ·  Astrid M Horstman, PhD (1)  ·  Barbara J Morgan, PhD, PT (1)  ·  Bianchi Giuseppe, MD (1)  ·  Bret Goodpaster, PhD (1)  ·  Cale Jacobs, PhD (1)  ·  Charles Bengtson, MD, MSc (1)

Results publications

PMID 32658300, PMID 41486497, PMID 19073787, PMID 19571282, PMID 19932542, PMID 20142543, PMID 21310077, PMID 21715517, PMID 22217192, PMID 23321647, PMID 24050942, PMID 24408116, PMID 24621999, PMID 25465809, PMID 25533774, PMID 26198842, PMID 26661322, PMID 27388615, PMID 28589652, PMID 29222139, PMID 29750475, PMID 29767459, PMID 29992039, PMID 30541065, PMID 30826452, PMID 31145418, PMID 31532959, PMID 31710528, PMID 32039215, PMID 32588430, PMID 32716358, PMID 33107592, PMID 33252490, PMID 33408462, PMID 33649520, PMID 34136782, PMID 34195577, PMID 34473343, PMID 35224732, PMID 35229827, PMID 35294537, PMID 35511890, PMID 35636733, PMID 36749631, PMID 37861929, PMID 37871959, PMID 38682786, PMID 39082471, PMID 40337980, PMID 40434633

NIH funding

1UG3AR077748-01 (1), 2008 (1), 2018 (1), K23HL127100 (1), P30AG021334 (1), R01AG076660 (1), R03DK096157 (1), R33DK070341 (1), U01AG050499 (1), U01AI105872 (1), U01DK061730 (1), U01HL105365 (1), U54AI117804 (1)